文献速递衰弱、肌少症与跌倒老年综合评估

改善住院老年人肌肉数量与功能干预措施的系统综述:面向急性肌少症治疗

Interventions to ameliorate reductions in muscle quantity and function in hospitalised older adults: a systematic review towards acute sarcopenia treatment.
PubMed 文献 · Age Ageing · 2021-01-01

该系统综述纳入44项研究共4522名住院老年人(平均年龄79.1岁),评估物理活动、营养、激素及神经肌肉电刺激等干预对肌肉功能/数量变化的效果。证据有限,最强证据支持多组分物理活动干预,但所有研究存在偏倚风险担忧且效应量不一致,目前尚无足够证据确定有效干预措施。

要点

  • 多组分物理活动干预证据相对最强,但研究间效应量不一致。
  • 营养、激素及神经肌肉电刺激干预证据有限,安全性已试验。
  • 所有研究存在至少一些总体偏倚风险担忧,真实效应确定性有限。

核心结论

  • 目前尚无足够证据支持有效干预措施改善住院老年人肌肉功能或数量的变化。
  • 最强证据支持多组分物理活动干预,但真实效应大小的确定性有限。
  • 治疗可能需要根据个体需求进行分层,并需更大规模测试组合干预的研究。

研究设计与样本

  • 系统综述检索MEDLINE、Embase、CINAHL和Cochrane图书馆,纳入随机对照试验。
  • 共纳入44项研究,4522名住院老年人,平均年龄79.1岁。
  • 由两名独立评审员提取数据并评估偏倚风险,计算干预前后肌肉功能/数量变化的标准均数差。

主要发现

  • 1项试验涉及睾酮(n=39),2项涉及生长激素(n=53),1项涉及诺龙(n=29),另1项涉及促红细胞生成素(n=141)。
  • 3项研究(n=206)测试了神经肌肉电刺激。
  • 有效性/功效证据有限,所有研究均存在至少一些总体偏倚风险担忧。

关键数值与推荐

  • 共识别9805篇文章,9614篇因标题/摘要被排除,147篇全文被排除。
  • 纳入44项研究,共4522名参与者,平均年龄79.1岁。

临床怎么用

  • 多组分物理活动干预可作为当前证据相对最强的选择,但需注意证据确定性有限。
  • 治疗应根据个体需求进行分层,不宜统一应用单一干预。
  • 多种干预已在不同设置下的异质人群中安全试验,但有效性尚不明确。

局限性

  • 所有研究均存在至少一些总体偏倚风险担忧。
  • 研究间效应量不一致,真实效应大小的确定性有限。
  • 目前证据不足以确定有效干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assimilate evidence for interventions to ameliorate negative changes in physical performance, muscle strength and muscle quantity in hospitalised older adults. METHODS: We searched for articles using MEDLINE, Embase, CINAHL and Cochrane library using terms for randomised controlled trials, older adults, hospitalisation and change in muscle quantity, strength or physical performance. Two independent reviewers extracted data and assessed risk of bias. We calculated standardised mean differences for changes in muscle function/quantity pre- and post-intervention. RESULTS: We identified 9,805 articles; 9,614 were excluded on title/abstract; 147 full texts were excluded. We included 44 studies including 4,522 participants; mean age 79.1. Twenty-seven studies (n = 3,417) involved physical activity interventions; a variety were trialled. Eleven studies involved nutritional interventions (n = 676). One trial involved testosterone (n = 39), two involved Growth Hormone (n = 53), one involved nandrolone (n = 29), and another involved erythropoietin (n = 141). Three studies (n = 206) tested Neuromuscular Electrical Stimulation. Evidence for effectiveness/efficacy was limited. Strongest evidence was for multi-component physical activity interventions. However, all studies exhibited at least some concerns for overall risk of bias, and considering inconsistencies of effect sizes across studies, certainty around true effect sizes is limited. CONCLUSION: There is currently insufficient evidence for effective interventions to ameliorate changes in muscle function/quantity in hospitalised older adults. Multiple interventions have been safely trialled in heterogeneous populations across different settings. Treatment may need to be stratified to individual need. Larger scale studies testing combinations of interventions are warranted. Research aimed at understanding pathophysiology of acute sarcopenia will enable careful risk stratification and targeted interventions.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Welch C, Majid Z, Greig C, et al. Interventions to ameliorate reductions in muscle quantity and function in hospitalised older adults: a systematic review towards acute sarcopenia treatment. Age Ageing. 2021. PMID: 33098419. doi:10.1093/ageing/afaa209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。